Shom Goel

Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation

Max Heckler, Lestat R Ali, Eleanor Clancy-Thompson, Li Qiang, Katherine S Ventre, Patrick Lenehan, Kevin Roehle, Adrienne Luoma, Kelly Boelaars, Vera Peters, Julia McCreary, Tamara Boschert, Eric S Wang, Shengbao Suo, Francesco Marangoni, Thorsten R Mempel, Henry W Long, Kai W Wucherpfennig, Michael Dougan, Nathanael S Gray, et al.

Journal article  |  2021  |  CANCER DISCOVERY

CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in m..

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx(R) Digital Spatial Profiler

Helga Bergholtz, Jodi M Carter, Alessandra Cesano, Maggie Chon U Cheang, Sarah E Church, Prajan Divakar, Christopher A Fuhrman, Shom Goel, Jingjing Gong, Jennifer L Guerriero, Margaret L Hoang, E Shelley Hwang, Hellen Kuasne, Jinho Lee, Yan Liang, Elizabeth A Mittendorf, Jessica Perez, Aleix Prat, Lajos Pusztai, Jason W Reeves, et al.

Journal article  |  2021  |  CANCERS

Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Under..

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

Laura M Spring, Shealagh L Clark, Tianyu Li, Shom Goel, Nabihah Tayob, Elene Viscosi, Elizabeth Abraham, Dejan Juric, Steven J Isakoff, Erica Mayer, Beverly Moy, Jeffrey G Supko, Sara M Tolaney, Aditya Bardia

Journal article  |  2021  |  NPJ BREAST CANCER

Patients with HER2+ metastatic breast cancer are often treated with a multitude of therapies in the metastatic setting, and additi..

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

Shom Goel, Joyce O'Shaughnessy, Antoinette R Tan, Boris Milev Krastev, Hope S Rugo, Philippe Georges Aftimos, Denise A Yardley, Andric Zoran, Curt Douglas Wolfgang, Jessica Sorrentino, Wenli Tao, Andrew Paul Beelen, Rajesh K Malik, Sarika Jain

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

TPS1107 Background: Trilaciclib is an intravenous (IV), highly potent and selective, reversible cyclin-dependent kinase (CDK) 4/6..

eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR , HER2 , node-positive, high-risk early breast cancer.

Sara M Tolaney, Lesley Fallowfield, Peter A Kaufman, Eva M Ciruelos, Mary Corona Gainford, Yi Lu, Karla Hurt, Heather Ann Wasserstrom, Yanyun Chen, Shom Goel

Conference Proceedings  |  2021  |  JOURNAL OF CLINICAL ONCOLOGY

TPS596 Background: Hormone receptor positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) ..

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)

Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache, Lama Karroum, Gerard G Hanna, Shankar Siva, Shom Goel, Steven David

Journal article  |  2021  |  BMC CANCER

BACKGROUND: The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast c..

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

April C Watt, Paloma Cejas, Molly J DeCristo, Otto Metzger-Filho, Enid YN Lam, Xintao Qiu, Haley BrinJones, Nikolas Kesten, Rhiannon Coulson, Alba Font-Tello, Klothilda Lim, Raga Vadhi, Veerle W Daniels, Joan Montero, Len Taing, Clifford A Meyer, Omer Gilan, Charles C Bell, Keegan D Korthauer, Claudia Giambartolomei, et al.

Journal article  |  2021  |  NATURE CANCER

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) were designed to induce cancer cell cycle arrest. Recent stu..

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

Steven David, Gwo Ho, Daphne Day, Marion Harris, Jennifer Tan, Shom Goel, Gerard G Hanna, Ranjana Srivastava, Gill Kruss, Lachlan McDowell, Michelle White

Journal article  |  2021  |  TRANSLATIONAL ONCOLOGY

Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is ..

Transforming growth factor beta in breast cancer: another new trick for the old dog

Kun-Hui Lu, Shom Goel

Journal article  |  2020  |  IMMUNOLOGY AND CELL BIOLOGY

Two recent papers from the laboratory of Professor Ming Li demonstrate that inhibition of transforming growth factor β specificall..

Trastuzumab-related cardiotoxicity: what do we know in 2020?

Jia Liu, Shom Goel, Jane McNeil Beith

Journal article  |  2020  |  TRANSLATIONAL CANCER RESEARCH